Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis

Table 5 Propensity score-adjusted multivariable cox regression analysis of prognostic factors associated with overall survival in the original cohort

Dependent: Survival (OS, status OS)		All, n (%)	HR (multivariable)
Gender	Male	90 (61.2)	-
	Female	57 (38.8)	0.32 (0.02-5.24, P = 0.421)
Age (year)	≤ 60	75 (51.0)	-
	> 60	72 (49.0)	1.10 (0.55-2.23, P = 0.782)
ECOG score	0-1	135 (91.8)	-
	2	12 (8.2)	0.92 (0.31-2.77, P = 0.880)
Primary tumor location	Right colon	49 (33.3)	-
	Left colon and rectum	98 (66.7)	1.47 (0.59-3.64, P = 0.404)
No. of metastatic organs	1	88 (59.9)	-
	≥ 2	59 (40.1)	3.78 (0.14-99.03, P = 0.424)
Liver metastasis	No	64 (43.5)	-
	Yes	83 (56.5)	3.16 (1.53-6.53, P = 0.002)
Lung metastasis	No	105 (71.4)	-
	Yes	42 (28.6)	0.81 (0.35-1.84, P = 0.610)
RAS	Wild type	22 (15.0)	-
	Mutation	28 (19.0)	0.91 (0.36-2.26, P = 0.833)
	Unknown	97 (66.0)	0.58 (0.27-1.26, P = 0.168)
Group	Control group	107 (72.8)	-
	Experimental group	40 (27.2)	0.74 (0.33-1.65, P = 0.468)
PS	mean ± SD	0.3 ± 0.1	719.14 (0.00-25553659310.55, P = 0.458)

n = 147, events = 50, Likelihood ratio test = 21.98 on 11 df (P = 0.025). OS: Overall survival; HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group; PS: Propensity score.